Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.36 HKD | -2.86% | +4.62% | -6.85% |
03/04 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
03/04 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
- Stock Market
- Equities
- 1672 Stock
- News Ascletis Pharma Inc.
- MarketScreener Strategies